Comunicati stampa

San Ramon, Calif. – September 2, 2020BioVentrix, Inc., developer of the first hybrid transcatheter device for left ventricular remodeling after a heart attack, today announced that the Company has resumed cases in the pivotal ALIVE Trial studying Less Invasive Ventricular Enhancement, or LIVE™ Therapy, using the Revivent TC™ Transcatheter Ventricular Enhancement System.


 

REVIVE-HF seeks to demonstrate superiority of the Revivent TC System to current guideline treatment for heart failure

SAN RAMON, Calif.--()--BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz (Germany) has joined the European REVIVE-HF clinical trial of the Revivent TC™ Transcatheter Ventricular Enhancement System as co-principal investigator.


SAN RAMON, Calif. –  February 18, 2020 – BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced that Gregg Stone, MD, of New York’s Mount Sinai Health System has signed on to the pivotal ALIVE Trial of the Revivent TC™ TransCatheter Ventricular Enhancement System as co-principal investigator.


Image

BioVentrix è una società privata di dispositivi medici con sede a San Ramon, in California, negli Stati Uniti.

Le nostre notizie

Contattaci

© 2020 BioVentrix. Tutti i diritti riservati. Realizzato da MedTech Momentum
Il marchio Revivent TC ™ è un marchio registrato a livello federale di proprietà di BioVentrix. Qualsiasi utilizzo non autorizzato è espressamente vietato.